The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee yesterday voted nine to five against approval of Arena Pharmaceutical (Nasdaq: ARNA) and Japanese drugmaker Eisai’s (TYO: 4523) obesity drug lorcaserin, sending the US firm’s shares tumbling 43% to $2.14 and casting another blow for weight loss products.
The negative decision comes just a day after a split vote by the same panel on whether or not to keep Abbott Laboratories currently marketed obesity drug Meridia (sibutramine) on the market and following a negative vote on Vivus’s Qnexa (phentermine/topiramate) earlier this year (The Pharma Letter September 16 and July 16).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze